GeneMedicine
Biotechnology Research
Seoul, Seoul-teukbyeolsi, Kr
11 employees
- Employees
- 11
GeneMedicine Overview
- Headquarters
- Seoul, Seoul-teukbyeolsi, Kr
- Phone Number
- Available in AeroLeads
- Website
- gene-medicine.com
- Industry
- Biotechnology Research
- Employees
- 11
- Founded
- 2014
- Funding
- 15.0M
- Company Email
- Available in AeroLeads
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
About GeneMedicine
GeneMedicine(GM) is a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies, aiming to transform the therapeutic outcomes for cancer patients. Using our proprietary adenovirus platform, we're developing several pipeline products that can be intratumorally and intravenously administered to selectively attack and eradicate tumor cells as well as potently stimulating multiple arms of antitumor immune response. Our viral immunotherapy has proven effective as both a standalone therapy and in combination with current standard of care, including immune checkpoint inhibitors (ICI). Intratumoral administration of GM oncolytic adenovirus offers several advantages over competitor products; (1) higher level of virus accumulation and localization in tumor tissues and (2) lower off-target systemic exposure, ultimately exerting potent therapeutic effect with minimal systemic toxicity. Our pipeline can effectively treat wide range of tumor types, including breast cancers (triple-negative and hormone receptor-positive), prostate cancer, melanoma, and non-melanoma skin cancer, desmoplastic cancers (like pancreatic cancer), and injectable visceral tumors that have spread to the liver, such as metastases from colorectal and lung cancer. To treat metastatic and recurrent cancers in late-stage cancer patients, we've developed systemic delivery platform for oncolytic viruses that avoids rapid blood clearance and inactivation by the immune system and various blood components. GM’s potent multi-armed oncolytic viral platform GM-OAd mediated oncolysis results in immunogenic cell death to trigger robust antitumor immune activation and memory formation to ensure long-term therapeutic benefit against cancer. GM has a highly scalable, low cost manufacturable platform offering highly versatile, innovative treatment options for patients with advanced or metastatic tumors.
GeneMedicine Contact Details
- People in AeroLeads
- 2
GeneMedicine Org Chart
Sample employees and titles| Name | Title | Location | Contact |
|---|---|---|---|
| Jinwoo Hong | Genemedicine Senior Engineer | Seoul, South Korea, Korea, Republic of |
View
|
| Chae-Ok Yun | Genemedicine Chief Executive Officer | Seoul, South Korea, Korea, Republic of |
View
|
Employees by Management Level
Senior / Lead
3 profiles
Executive
2 profiles
Manager
1 profile
GeneMedicine Tech Stack
Engineering
2 profiles
Compare Similar Companies to GeneMedicine
OmniBRx Biotechnologies Pvt Ltd
Biotechnology Research
Akela Pharma, Inc.
Pharmaceutical Manufacturing
ViGenCell(바이젠셀)
Biotechnology Research
Cytovant Sciences Co., Ltd.
Biotechnology Research
LMNTIC Biotech
Biotechnology Research
Izumi Biosciences
Agriculture, Construction, Mining Machinery Manufacturing
Cloud Pharma
International Trade And Development
BiotechStage
Biotechnology Research
Celli Technologies Inc
Biotechnology
Salvé Technologies
Biotechnology Research